MedTrace Logo

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3571

Last updated 2019-07-05

No results posted yet for this study

Summary

RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.

PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.

Conditions

Interventions

PROCEDURE

assessment of therapy complications

By dental and medical assessments.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Novartis

    collaborator INDUSTRY

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Catherine Van Poznak, MD · University of Michigan Rogel Cancer Center

  • Julie R. Gralow, MD · Seattle Cancer Care Alliance

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • United States
  • Mexico
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00874211 on ClinicalTrials.gov